BioTime Co-CEO Dr. Michael West to Deliver Presentation as Part of Biotech Panel at Mauldin Economics’ Strategic Investment...
May 23 2017 - 4:30PM
Business Wire
BioTime, Inc. (NYSE MKT: BTX), a clinical-stage
biotechnology company developing and commercializing products
addressing degenerative diseases, today announced that Co-Chief
Executive Officer Michael D. West, Ph.D., is delivering a
presentation as part of a panel on biotechnology at the Mauldin
Economics’ Strategic Investment Conference on Wednesday, May 24 at
3:20pm EDT at the Omni Orlando Resort in Florida.
In his presentation, "Emerging Trends in Regenerative
Medicine and Aging,” Dr. West will provide an update on product
development by the BioTime group of companies, focusing on the
strategy of transplanting young healthy cells into tissues
afflicted with age-related degenerative disease. He will also
discuss new products planned for development at BioTime's
recently-announced new subsidiary, AgeX Therapeutics.
More information about Mauldin Economics’ Strategic Investment
Conference can be found here.
About BioTime
BioTime is a clinical-stage biotechnology company focused on
developing and commercializing products addressing degenerative
diseases. Our clinical programs are based on two platform
technologies: pluripotent stem cells and cell/drug delivery
platform technologies. The foundation of our core therapeutic
technology platform is pluripotent cells that are capable of
becoming any of the cell types in the human body. The foundation of
our cell delivery platform is its HyStem® cell and drug delivery
matrix technology. The Company’s current clinical programs are
targeting three primary sectors, aesthetics, ophthalmology and
cell/drug delivery. We also have significant equity holdings in two
publicly traded companies, Asterias Biotherapeutics, Inc.
(“Asterias”) and OncoCyte Corporation (“OncoCyte”), which we
founded and which, until recently, were our majority-owned
consolidated subsidiaries.
BioTime common stock is traded on the NYSE MKT and TASE under
the symbol BTX. For more information, please visit
www.biotimeinc.com or connect with the company on Twitter,
LinkedIn, Facebook, YouTube, and Google+.
To receive ongoing BioTime corporate communications, please
click on the following link to join our email alert list:
http://news.biotimeinc.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170523006289/en/
Investor ContactEVC Group, Inc.Michael Polyviou,
212-850-6020mpolyviou@evcgroup.comorMedia Contact:Gotham
Communications, LLCBill Douglass,
646-504-0890bill@gothamcomm.com
Brooklyn ImmunoTherapeut... (AMEX:BTX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Brooklyn ImmunoTherapeut... (AMEX:BTX)
Historical Stock Chart
From Sep 2023 to Sep 2024